Clinical trial
Teclistamab and Mezigdomide for Relapsed/Refractory Multiple Myeloma
NCT07105059 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Teclistamab and Mezigdomide for Relapsed/Refractory Multiple Myeloma
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- August 8, 2025
- Completion date
- August 8, 2028
- Enrollment
- 18 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.